Solid Biosciences Inc. — Director's Dealing 2022

Dec 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2022-12-02

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund, L.P. (Director, 10% Owner)
Reporting Person: Kolchinsky Peter (Director, 10% Owner)
Reporting Person: Shah Rajeev M. (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-02	Common Stock	A	2163120	$7.05	Acquired	2987644	Indirect
2022-12-02	Common Stock	A	300412	—	Acquired	3288056	Indirect
2022-12-02	Common Stock	A	109661	—	Acquired	109661	Indirect

Footnotes

F1: Acquired from the Issuer pursuant to the Securities Purchase Agreement dated September 29, 2022.

F2: Reflects the Issuer's reverse stock split that occurred on October 27, 2022.

F3: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F4: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022.

F5: Held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund").

F6: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.